CETAMOLOL HYDROCHLORIDE

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H26N2O4.ClH
Molecular Weight	346.85
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

Cl.CNC(=O)COC1=C(OCC(O)CNC(C)(C)C)C=CC=C1

InChI

InChIKey=CRYTUFSEASFGMP-UHFFFAOYSA-N

InChI=1S/C16H26N2O4.ClH/c1-16(2,3)18-9-12(19)10-21-13-7-5-6-8-14(13)22-11-15(20)17-4;/h5-8,12,18-19H,9-11H2,1-4H3,(H,17,20);1H

HIDE SMILES / InChI

Molecular Formula	C16H26N2O4
Molecular Weight	310.3886
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Cetamolol is a beta adrenergic antagonist with intrinsic sympathomimetic activity, patented by Imperial Chemical Industries Ltd for cardiovascular disease treatment. The average plasma half-life of cetamolol is 6.4 hours in humans and peak serum levels are reached 1 to 2 hours after drug intake; oral doses as low as 10 mg produced significant reductions in exercise-induced tachycardia 24 hours after drug administration. Cetamolol is approximately three times as potent as atenolol in blocking exercise-induced tachycardia.